InhibrxINBX
About: Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Employees: 161
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
351% more call options, than puts
Call options by funds: $993K | Put options by funds: $220K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
2.59% less ownership
Funds ownership: 77.11% [Q4 2024] → 74.52% (-2.59%) [Q1 2025]
9% less funds holding
Funds holding: 101 [Q4 2024] → 92 (-9) [Q1 2025]
12% less capital invested
Capital invested by funds: $172M [Q4 2024] → $151M (-$21M) [Q1 2025]
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
50% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 36
Research analyst outlook
We haven’t received any recent analyst ratings for INBX.
Financial journalist opinion









